Inventurus Knowledge Solutions IPO: Subscription Status, GMP, and Should You Invest?
Inventurus Knowledge Solutions IPO fully subscribed on Day 1; GMP suggests a 28% premium listing. Explore subscription details, price band, allotment dates, and expert opinions. The IPO offers promising prospects in the US healthcare solutions market.
The highly anticipated Inventurus Knowledge Solutions IPO has created a buzz among investors. This Rs 2,497.92 crore IPO opened on December 12 and will remain open until December 16, excluding holidays on December 14 and 15. On its first day, the IPO was fully subscribed, and its grey market premium (GMP) hints at a premium listing. Here’s everything you need to know before deciding whether to invest.
Inventurus Knowledge Solutions IPO Subscription Status
The IPO witnessed robust demand on its first day, with a total subscription of 1.36x.
- Retail Investors: Oversubscribed by 1.67 times.
- Qualified Institutional Buyers (QIB): Fully subscribed at 1.54x.
- Non-Institutional Investors (NII): Subscribed at 79% of the allocated shares.
The subscription period is open from 10:00 am to 5:00 pm on trading days, and investors have until December 16 to participate.
IPO Details
- Price Band: Rs 1,265 to Rs 1,329 per share.
- Lot Size: 11 shares per lot.
- Registrar: Link Intime India.
- Book Running Lead Managers: ICICI Securities, Jefferies India, JM Financial, J.P. Morgan India, and Nomura Financial Advisory.
The IPO is 100% book-built, meaning the price will be determined based on investor demand.
GMP Hints at Strong Listing Gains
As per the latest updates, the grey market premium (GMP) for the Inventurus Knowledge Solutions IPO is Rs 375. With a cap price of Rs 1,329, the estimated listing price stands at Rs 1,704, representing a potential 28.22% premium gain.
Inventurus Knowledge Solutions IPO Allotment and Listing Dates
- Allotment Date: December 17, 2024.
- Refund/Credit to Demat Accounts: December 18, 2024.
- Listing Date: December 19, 2024.
The shares will be listed on both the BSE and NSE, with a strong debut expected based on the current GMP trends.
Expert Recommendations: Should You Invest?
Choice Broking:
The brokerage views Inventurus Knowledge Solutions (IKSL) as a promising player in the niche US healthcare solutions sector. Its care enablement platform caters to physician enterprises in the US, Canada, and Australia. However, the aggressive valuation of 9.7x EV/Sales raises concerns. Choice Broking recommends subscribing for long-term growth.
KR Choksey:
KR Choksey highlights IKSL’s strong growth history, robust technological differentiation, and scalable asset-light business model. At a valuation of 61.6x P/E, the IPO is considered attractive, and the brokerage assigns a "Subscribe" rating.
SMC Global Securities:
While acknowledging the company’s scalability and ability to address key pain points in healthcare, SMC Global Securities points out the risks of revenue dependency on the US market. SMC assigns a 2/5 rating, advising caution.
What Makes IKSL Unique?
Inventurus Knowledge Solutions specializes in reducing administrative burdens for healthcare providers through a comprehensive platform. The company has a strong presence in the US market, offering outpatient and inpatient care enablement services.
With the acquisition of Aquity Holdings, IKSL has significantly expanded its client base, boosting both revenue and profitability. The company’s technological edge and alignment with the evolving needs of the US healthcare market position it for sustainable growth.
Risks to Consider
- Valuation Concerns: The IPO is priced aggressively, raising questions about immediate returns.
- Sector Concentration: Heavy reliance on the US healthcare sector makes the company vulnerable to market-specific risks.
- Geographic Dependency: Limited diversification outside the US poses a potential growth challenge.
Also Read: How to Invest in US Stocks: A Simple Guide for Indians - Read Now